The first twice-daily injectable HIV prevention drug based on lenacapavir has received CHMP recommendation for authorization, promising an effective and affordable solution.
Cristina Petrache
Health
Foto pexels.com
Always see our news on Google
Lenacapavir is the first twice-daily injectable drug for the prevention of HIV infection, with 99.9% efficacy in clinical trials. Recommended by the CHMP, this treatment simplifies prevention by eliminating the need for daily tablets. In Romania, where the cost of HIV treatment is high, the new PrEP could reduce costs and improve access for vulnerable people. Approved at European level, this drug represents a significant opportunity to transform HIV prevention into public health policy.
Sources
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o şansă uriaşă pentru prevenţia HIV în România
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o șansă uriașă pentru prevenția HIV în România
Omenirea, mai aproape ca niciodată de a opri virusul HIV. Europa a autorizat tratamentul revoluționar
E.U. regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission
Latest News
13:28
Two suicides and two suicide attempts among the officials in the office of Prime Minister Sébastien Lecornu
13:27
The EU receives another 1.4 billion euros from frozen Russian assets, while total revenues reach 8 billion.
13:25
Home burglaries have decreased by 38% in the EU over a decade, but remain above the minimum level of 2021.
13:22
Two young people are being investigated for the theft of 14 tablets from a school in Cluj County.
13:15
Accusations of child pornography investigated by DIICOT in the case of a former presidential advisor
See more news
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
